HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment (Q36806044)
Jump to navigation
Jump to search
scientific article published on 26 February 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment |
scientific article published on 26 February 2013 |
Statements
1 reference
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment (English)
1 reference
HPS2-THRIVE Collaborative Group
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference